Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ambrisentan high-dose versus low-dose study in pulmonary arterial hypertension
NL-OMON34214Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ambrisentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Primary endpoint: Adverse events. Planned start Aug 2010; status: withdrawn.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON34214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34214.